Key words
differentiated thyroid carcinoma - response to therapy - thyroglobulin - stimulation
- recurrence
Introduction
In patients with differentiated thyroid carcinoma (DTC) who received radioactive iodine
(RAI) after total thyroidectomy, evaluation of the response to initial therapy starts
with the measurement of basal thyroglobulin (b-Tg) and anti-Tg antibodies (TgAb) and
neck ultrasonography (US) [1]
[2]. In patients without an apparent tumor on US, especially low- or intermediate-risk
cases, initial categorization of the response to therapy as excellent, indeterminate
or incomplete is fundamental for management. Diagnostic whole-body scanning (DxWBS)
is not necessary in the case of an excellent response [1 (Recommendation 66 - ATA
Guidelines),2]. On the other hand, imaging methods other than US should be performed
in patients with an initial biochemical incomplete response to rule out structural
disease [2]. In the follow-up of low-risk patients with an excellent response, repetition of
US is not necessary if b-Tg and TgAb remain negative [1 (Recommendation 65D - ATA
Guidelines)]. The measurement of b-Tg is recommended every 12–24 months after an excellent
response [1 (Recommendation 62 C - ATA Guidelines),2] versus 6–12 months after an
indeterminate or incomplete response [1 (Recommendation 62E - ATA Guidelines),2].
Repetition of stimulated Tg (s-Tg) is not recommended after an excellent response
[1 (Recommendation 63B - ATA Guidelines),2] but may be considered after indeterminate
and biochemical incomplete responses accompanied by b-Tg reduction during follow-up
[1 (Recommendation 63 C - ATA Guidelines),2]. Finally, the serum TSH target (<0.1,
between 0.1 and 0.5, or between 0.5 and 2 mIU/l) differs among response categories
[1 (Recommendation 70 - ATA Guidelines),2]. These differences exist because the risk
of developing structural disease during follow-up is different for each of the three
categories [1].
Basal Tg measured by a second-generation assay or s-Tg can be used to define the response
to therapy [1 (Recommendation 63 A - ATA Guidelines),2]. However, s-Tg may not correspond
to the same category as b-Tg, a fact that can lead to a change in category of the
patient if the first is obtained. Unfortunately, current guidelines do not define
“if” or “when” s-Tg should be measured when second-generation assays are used [1]
[2]
[3]
[4].
The aim of this study was to evaluate the change in the response to initial therapy
category when s-Tg is obtained in order to define for which patients its measurement
would be indicated, even when second-generation Tg assays are used. As this doubt
especially applies to low- or intermediate-risk patients who received RAI and who
do not have apparent disease on US or positive TgAb, this was the population of the
study.
Compliance with ethical standards
The study was approved by the Research Ethics Committee of our institution.
Patients and Methods
Patients
At our service, investigation after initial therapy of DTC starts with the measurement
of b-Tg and TgAb and neck US. We do not obtain s-Tg in patients not receiving RAI
or patients treated with RAI when US already reveals a tumor or b-Tg is already elevated.
Since 2006, Tg has been measured with a second-generation assay [5]. Thus, the patients included in this study were those treated with total thyroidectomy
and RAI who had b-Tg ≤1 ng/ml and US without abnormalities 9–12 months after initial
therapy and s-Tg obtained on that occasion. Patients classified as high risk according
to the American Thyroid Association (ATA) [1] or those with TgAb were excluded.
Initial evaluation
Based on b-Tg, the response to initial therapy was classified as excellent if<0.2 ng/ml
and as indeterminate if between 0.2 and 1 ng/ml [1]
[2]
[3]
[4]. Stimulated Tg was obtained 72 h after administration of the second rhTSH ampoule
[6] or after 4 weeks without levothyroxine [with TSH>30 mIU/l]. Based on s-Tg, the response
to therapy was classified as excellent if<1 ng/ml, as indeterminate if between 1 and
10 ng/ml, and as biochemical incomplete if>10 ng/ml [1]
[2]
[3]
[4].
During initial evaluation, imaging methods other than US [neck, chest and mediastinal
computed tomography (CT), fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT]
were performed if s-Tg ≥2 ng/ml. Empirical 131I therapy was not performed in these patients.
Follow-up
The patients were maintained on 0.1–2 mIU/l TSH and were followed up by clinical examination,
measurement of Tg and TgAb at intervals of 6–12 months, and annual neck US. Imaging
methods other than US were performed if b-Tg ≥1 ng/ml.
Methods
US was performed with a linear multifrequency transducer for morphological analysis
(B-mode) and for power Doppler evaluation. All suspected lesions apparent on the scans
[7]
[8] were evaluated by US-guided fine-needle aspiration biopsy. CT with contrast was
performed on 5-mm sequential sections. FDG-PET/CT was carried out according to a recommended
protocol [9]
[10]. All images were analyzed by experienced Radiology or Nuclear Medicine specialists.
Structural disease was defined based on the imaging results, cytology or histology,
and/or unequivocal ectopic uptake (excluding false-positive results) on post-therapy
WBS (RxWBS) or FDG-PET/CT. Tumor recurrence was defined as structural disease diagnosed
after s-Tg measurement in patients without apparent disease in the initial evaluation.
Chemiluminescent assays were used for the measurement of Tg [Access Thyroglobulin
Assay, Beckman Coulter, Fullerton, CA (functional sensitivity of 0.1 ng/ml at our
laboratory [11]) and TgAb [Immulite 2000, Diagnostic Products Corporation, Los Angeles, CA (reference
value of up to 40 IU/ml) or ARCHITECT Anti-Tg, Abbott Laboratories, IL, USA (reference
value of up to 4.11 IU/ml)].
Statistical analysis
Subgroups were defined by combining the category of response to therapy based on u-Tg
with the category defined by s-Tg. Fisher’s exact test or chi-squared test was used
to detect differences in the rate of recurrence between the subgroups. These tests
were also used to compare the rate of recurrence among low and intermediate risk patients.
A p-value less than 0.05 was considered significant.
Results
Patients
We evaluated 304 patients with DTC who were initially treated with total thyroidectomy
and RAI and who had no clinically apparent disease or disease detected on neck US
and were negative for TgAb 9–12 months after initial therapy. Basal Tg ranged from
undetectable to 1 ng/ml (median 0.11 ng/ml). Based on b-Tg, 196 patients had an excellent
response and 108 had an indeterminate response to therapy. The characteristics of
the 304 patients are shown in [Table 1].
Table 1 Characteristics of the 304 patients.
|
Sex
|
|
|
Female
|
244 (80.2%)
|
|
Male
|
60 (19.7%)
|
|
Age
|
14–81 years (mean 49 years)
|
|
≤55 years
|
198 (65.1%)
|
|
>55 years
|
106 (34.8%)
|
|
Histology
|
|
|
Papillary
|
284 (93.4%)
|
|
Follicular
|
12 (4%)
|
|
Hurthle Cell
|
8 (2.6%)
|
|
ATA initial risk
|
|
|
Low risk*
|
91 (30%)
|
|
Intermediate risk
|
213 (70%)
|
|
Initial therapy
|
|
|
Completion following lobectomy/primary total thyroidectomy
|
22 (7.2%)/282 (92.7%)
|
|
Lymph node dissection: therapeutic/elective/not performed
|
123 (40.4%)/10 (3.3%)/171 (56.2%)
|
|
131I therapy: 30–50 mCi/100 mCi–150 mCi
|
201 (66.1%)/103 (33.9%)
|
ATA: American Thyroid Association. * All with tumors>1 cm and none with the noninvasive encapsulated follicular variant.
Stimulated Tg
Based on s-Tg, a change in category occurred in 10.2% (20/196) of the patients with
an excellent response (all to indeterminate response) and in half the patients with
an indeterminate response (44.4% to excellent response and 5.5% to biochemical incomplete
response). The number of patients who changed the category of the response to therapy
is shown in [Fig. 1].
Fig. 1 Patients who changed the category of the response to therapy. Excellent response
(white boxes), Indeterminate response (gray boxes), Biochemical incomplete response
(black box).
Frequency of recurrence
After s-Tg measurement, the patients were followed up for 24–120 months (median 62
months).
Structural disease has so far been detected in 9 patients, including 8 with cervical
metastases (detected by US in 6 and by FDG-PET in 2) and one with pulmonary metastases
(detected by CT). Tumor recurrence was detected for 6–72 months (median 36 months)
after s-Tg measurement. After surgery, six patients were free of disease (undetectable
nonstimulated Tg, negative TgAb, US without anomalies) and one patient continued to
have detectable nonstimulated Tg<1 ng/ml and no apparent tumor was detected by the
imaging methods. In the last evaluation, two other patients had persistent disease
but stable ([Table 2]).
Table 2 Frequency of tumor recurrence considering the response to therapy based on b-Tg and
s-Tg.
|
Response based on b-Tg [recurrence (%)]
|
Response based on s-Tg [recurrence (%)]
|
|
Excellent
|
Indeterminate
|
Incomplete
|
|
Excellent [1/196 (0.5%)]
|
0/176
|
1/20 (5%)
|
|
|
Indeterminate [8/108 (7.4%)]
|
0/48
|
6/54 (11.1%)
|
2/6 (33.3%)
|
|
Total [9/304 (3%)]
|
0/224
|
7/74 (9.4%)
|
2/6 (33.3%)
|
b-Tg: Basal thyroglobulin; s-Tg: Stimulated thyroglobulin.
Using b-Tg for definition of the response to therapy, the recurrence rate was significantly
lower for the excellent response category (0.5%) compared to the indeterminate category
(7.4%) (p=0.001). Using s-Tg, this difference was also observed [0 vs. 9.4% (p=0.0001)].
No difference was found in the frequency of recurrence between the excellent [0.5
vs. 0% (p=0.46)] or indeterminate responses [7.4 vs. 9.4% (p=0.78)] using either b-Tg
or s-Tg, respectively.
One case of recurrence was observed among patients with an initial excellent response
(based on b-Tg) but whose response changed to indeterminate after s-Tg, while no disease
was detected in those who remained in the initial category; however, this difference
was not significant (p=0.1).
In patients with an indeterminate response (based on b-Tg), no case of recurrence
was detected among those whose response changed to excellent after s-Tg, while 11.1
and 33.3% of those who remained in the initial category or whose response changed
to biochemical incomplete, respectively, had structural disease. The frequency was
significantly lower in the first group.
[Table 1] shows the rate of recurrence in each subgroup. The frequency of structural disease,
percentage of change in category or recurrence rates did not differ between low- and
intermediate risk patients and these patients were therefore grouped.
Discussion
We first address some characteristics that differentiate this work from previous studies
that also reported the results of s-Tg in patients with low b-Tg measured with second-generation
assays. To increase clinical applicability, the present study evaluated the cut offs
currently proposed by ATA [1] and other societies [2]
[4]
[12]
[13] to define the response to thyroidectomy followed by RAI, that is, 0.2 and 1 ng/ml
for b-Tg and 1 and 10 ng/ml for s-Tg. As also currently recommended, US was obtained
in all patients during initial evaluation [1]
[2]
[3]
[4]
[12]
[13]. This imaging method is the minimum required to rule out structural disease [1]
[2]
[3]
[4]
[12]
[13]. In addition, the omission of US during initial evaluation may overestimate the
long-term frequency of neck recurrence. Empirical 131I therapy was not performed in our patients. We evaluated not only the results of
s-Tg but also the recurrence rate in different subgroups after follow-up for up to
120 months. Finally, high-risk patients were excluded since even an excellent response
in this group might be associated with a considerable frequency of persistent or recurrent
disease [1]
[2]
[3]
[14]
[15]
[16].
In the group with an initial excellent response to therapy based on b-Tg, all 20 patients
who changed category after s-Tg were classified as indeterminate response. When this
change occurred, the recurrence rate was 5%. Brassard et al. [17] found recurrence in 11% of 26 patients with b-Tg ≤0.27 ng/ml but s-Tg>1.4 ng/ml.
The authors of that study did not routinely perform US to rule out apparent disease
already during initial evaluation, as recommended [1]
[2]
[3]
[4]
[12]
[13]. A rate of structural recurrence of about 10% has also been reported in three other
studies involving a smaller number of patients initially without US abnormalities
and with b-Tg ≤0.1 ng/ml [18], 0.15 ng/ml [19], or 0.2 ng/ml [20], but s-Tg>1 ng/ml. In contrast, Hu et al. [21] detected no recurrence after 36 months in 25 patients with b-Tg ≤ 0.2 ng/ml but
s-Tg>1 ng/ml. Although the change from an excellent to indeterminate response may
identify a subgroup of patients with a higher recurrence risk than those whose s-Tg
confirms an excellent response, this conversion occurs in a minority of patients (present
study, [17]
[18]
[19]
[20]
[21]
[22]). This low frequency of change in category, together with the results above showing
that, even if conversion occurs, only 10% of patients or less develop recurrence,
renders the measurement of s-Tg unattractive in patients with an excellent response
to initial therapy based on b-Tg. In addition, one must consider the cost of rhTSH
or the risks and complications of acute hypothyroidism [23].
Among the 108 patients with an indeterminate response based on b-Tg, a change to the
excellent response category after s-Tg was observed in 44%. In agreement with this
finding, Brassard et al. [17] showed that 41% of 117 patients with b-Tg>0.27 ng/ml had s-Tg<1.4 ng/ml, Malandrino
et al. [19] that 36% of 69 patients with b-Tg between 0.15 and 1 ng/ml had s-Tg ≤1 ng/ml, and
Trimboli et al. [24] that 39% of 57 patients with b-Tg>0.1 ng/ml had s-Tg ≤ 1 ng/ml. Even more important,
the risk of recurrence in patients whose response changed from indeterminate to excellent
after s-Tg was compatible with the last category. None of the 48 patients developed
recurrence, similar to the observation in patients in which both, b-Tg and s-Tg, indicated
an excellent response. Despite the use of a cut off that was slightly different from
the currently recommended [1]
[2]
[3]
[4]
[12]
[13], similar results have been reported by Brassard et al. [17] who demonstrated recurrence in only 1/48 patients (2%) with b-Tg>0.27 ng/ml but
s-Tg<1.4 ng/ml; by Malandrino et al. [19] who found no short-term recurrence in 25 patients with b-Tg>0.15 ng/ml but initial
US showing no tumor and s-Tg ≤1 ng/ml; and by Trimboli et al. [24] who did not detect disease in 22 patients with b-Tg>0.1 ng/ml but s-Tg ≤1 ng/ml.
Different from these results, the frequency of recurrence was 7.5% in patients with
an indeterminate response based only on b-Tg and 11% when both, b-Tg and s-Tg, defined
this category. In agreement, a recent study also showed biochemical or structural
recurrence after follow-up for 68 months (median) in 9% of patients initially classified
as having an indeterminate response based on both b-Tg and s-Tg [25].
Considering the frequency of change to an excellent response and the consequences
of this change, obtaining s-Tg seems to be interesting in patients with an initial
indeterminate response based on b-Tg. With this change in category, these patients
may no longer require to be submitted to US repetition if b-Tg and TgAb remain stable
[1], the interval of Tg measurement can be increased to every 12–24 months [1]
[2], repetition of s-Tg is not recommended [1]
[2], and TSH suppression is not necessary [1]
[2]. Secondly, in some of our patients, the indeterminate response changed to biochemical
incomplete after s-Tg, a finding that requires more frequent follow-up, better investigation,
and more intense TSH suppression [1]
[2]
[3]. Indeed, although the number of patients with this change in category after s-Tg
was small, the risk of recurrence was high in this group.
We recognize that the retrospective design of the study is a limitation; however,
all patients were seen at the same institution, were evaluated by the same professionals,
and were submitted to the same follow-up and investigation protocol. Notably, patients
with elevated Tg (initial s-Tg ≥2 ng/ml or b-Tg ≥1 ng/ml during follow-up) were investigated
by neck US, CT, FDG-PET/CT [26]
[27], a highly sensitive combination for the detection of metastases [27]. Another limitation is the time of follow-up, with a median of 60 months; however,
it is known that 3/4 of recurrences occur in these first years [17]. In addition, the time was similar among the groups whose recurrence rates were
compared (data not shown). Although we included low-risk patients, all they had tumors>1 cm,
none with the noninvasive encapsulated follicular variant, and the frequency of structural
disease, percentage of change in category or recurrence rates did not differ between
low- and intermediate risk patients. Finally, one group not evaluated in the present
study were patients with a biochemical incomplete response based on b-Tg.
The results of this study suggest that in low- or intermediate-risk patients treated
with RAI, s-Tg better defines the response to therapy when it is classified as indeterminate
based on b-Tg using a second-generation assay. However, s-Tg is not necessary when
b-Tg defines the response to therapy as excellent.
Funding
This work was supported by the National Council for Scientific and Technological Development
(CNPq).
